2000 Pilot Study Grants - Grants 22-43

Share

Funding from The Parkinson Alliance helped to finance the following Parkinson's research. Grantees were selected by scientific review committees of participating organizations. Abstracts and reports are available by clicking the underlined grants.

22. In Utero Gram-Negative Bacterial Infections as A Risk Factor for Parkinson’s Disease
Dave Anthony Gayle, Ph.D.
Rush Presbyterian-St. Luke’s Medical Center, Chicago, Ilinois

23. Extracellular Syuperoxide Dismutase in Parkinson’s Disease
Tim D. Oury, M.D., Ph.D.
University of Pittsburgh, Pittsburgh, Pennsylvania

24. Activation of Cell Cycle Machinery Mediates Neuronal Cell Death Following Proteasomal Inhibition in a Cellular Model of Parkinson’s Disease
Leonidas Stefanis, M.D., Ph.D.
Columbia University, New York, New York

25. A Dopaminergic Cell Line for Transplantation Therapy of Parkinson’s Disease
Zuo-Zhong Wang, Ph.D.
University of Pittsburgh, Pittsburgh, Pennsylvania

26. Low Oxygen and Erythropoietin-Mediated Protection of Dopaminergic Neurons
Marie Csete, M.D., Ph.D.
University of Michigan, Ann Arbor, Michigan

27. Group I Metabotropic Glutamate Receptors in the Basal Ganglia – Involvement in D2 Receptor Signaling and Dopamine Nerve Cell Survival in Models of Parkinson’s Disease
Kjell Fuxe, M.D.
Karolinska Institute, Stockholm, Sweden

28. Identification of Susceptibility Genes for Parkinson’s Disease by Transmission Dis-equilibrium Testing in Discordant
Siblings
Thomas Gasser, M.D., Ph.D.
Ludwig-Maximilians University, Munich, Germany

29. Transfectants as a Model to Study the Synucleinopathy of Parkinson’s Disease
Li-Wen Ko, Ph.D.
Mayo Clinic – Jacksonville, Florida

30. Dopaminergic Cell Death Due to Hypersensitive Nicotinic Acetlcholine Receptors: Relevance to Parkinson’s Disease
Henry A. Lester, Ph.D.
California Institute of Technology, Pasadena, California

31. Subcellular Localization and Phosphyorylation of NMDA Receptor Proteins in Cultured Striatal Neuron
Jin Hong Li, Ph.D.
Massachusetts General Hospital, Boston, Massachusetts

32. Characterization of Individual Dopaminergic Cells in the Adult Olfactory Bulbs: Replacement Neurons for Parkinson’s Disease
Nian Liu, Ph.D.
Cornell University Medical College, at the W.M. Burke Medical Research Institute, White Plains, New York

33. Alpha-Synuclein mRNA Expression in Human Synucleinopathy Brain Tissue
David W. Miller, Ph.D.
Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts

34. Methods for Evaluating Mitochondrial Function in Identified Nigral Neurons
Ian Reynolds, Ph.D.
University of Pittsburgh School of Medicine, Pittsburgh , Pennsylvania

35. A Cellular Model of Parkinson’s Disease. Proteasomal Inhibition Leads to Formation of Ubiquitinated Inclusions and Cell Death in Rat Pheochromocytoma PC12 Cells
Leonidas Stefanis, M.D., Ph.D.
Columbia University, College of Physicians and Surgeons, New York, New York

36. Changes Expression of Voltage Dependent Potassium Channels in Rodent Model of Parkinson’s Disease
Tatiana Tkatch, Ph.D.
Northwestern University, Evanston, Illinois

37. Molecular Mimicry Between Epstein-Barr Virus and Alpha-Synuclein: EBV-Induced Autoantibodies to Alpha-Synuclein in Parkinson’s Disease
John Woulfe, M.D., Ph.D., FRCPC
Hamilton Health Sciences Centre, Hamilton, Ontario, Canada

38. Molecular chaperones and Huntington’s disease--updated 8/2002
Donald B. DeFranco, Ph.D.
University of Pittsburgh, Pittsburgh, Pennsylvania

39. Assessing postural rigidity from quiet stance in patients with Parkinson’s disease--updated 8/2002
Carson Chow, Ph.D.
University of Pittsburgh, Pittsburgh, Pennsylvania

40. Effects of unilateral intrastriatal dopaminergic grafts in MPTP-treated hemiparkinsonian monkeys--updated 8/2002
Nicholas I. Bohnen, M.D., Ph.D.
University of Pittsburgh, Pittsburgh, Pennsylvania

41. Caspase dependent and independent pathways for cell death mechanisms in relation to Parkinson’s disease--updated 8/2002
Jun Chen, M.D.
University of Pittsburgh, Pittsburgh, Pennsylvania

42. Transgenic and knockout animal facility--updated 8/2002
Tim D. Oury, M.D., Ph.D.
University of Pittsburgh, Pittsburgh, Pennsylvania

43. Neuroprotection of vasicular monoamine transporter in the pathogenesis of Parkinson’s disease--updated 8/2002
Yongjian Liu, M.D., Ph.D.
University of Pittsburgh, Pittsburgh, Pennsylvania


Return to 2000 Pilot Study Grants - Grants 1-21
Return to Top

Click for a printer friendly version